Archive · 9 Oct 2026
Two Soaring Stocks Face Questions Over Cash and Oversight
Two companies have had big increases in their share prices.
Kwality Pharmaceuticals makes generic medicines and has reported rising profits.
But many customers take a long time to pay it, so some of its reported earnings have not yet turned into cash.
The company says its collections have recently improved and it wants to improve them further.
Maxgrow India trades in scrap metal and has also reported rising profits.
Its auditor, however, raised concerns about records, late filings, and other controls.
Few of Maxgrow’s shares are available to public investors because its promoter owns more than 90%.
The article says investors should watch the companies’ next results for evidence about cash collection, audits, taxes, and share ownership.
Kwality Pharmaceuticals’ share price rose 296% in a year, while Maxgrow India’s rose 852%, according to the article.
Kwality’s net profit increased from Rs 12 crore in June 2025 to Rs 26 crore in June 2026, but debtor days had risen to 203 in FY26.
Kwality management said receivables improved to about 165–170 days and set FY27 guidance of revenue above Rs 700 crore and profit above Rs 109 crore.
Maxgrow’s quarterly profit rose for five straight quarters to Rs 199 crore in June 2026, while its latest-quarter sales dipped.
Maxgrow’s auditor raised governance and reporting concerns, and its promoter stake above 90% leaves less than 10% with public shareholders.
- Who
- Kwality Pharmaceuticals and Maxgrow India, two Indian listed companies.
- What
- An analysis of their rising profits and share prices, alongside concerns about cash collection at Kwality and audit, reporting, and share-ownership issues at Maxgrow.
- When
- The article cites results through June 2026 and share-price gains measured as of 8 October 2026; it says September-quarter results are due soon.
- Where
- India; Kwality is based in Punjab, and Maxgrow’s resolution plan was approved by the NCLT Mumbai bench.
- Why
- The article examines whether the companies’ reported profit growth is supported by cash generation and sufficiently clear financial reporting.
Potential strengths
Key risks
Kwality’s growth and collections
Potential strengths
Profit has risen, and management said receivables improved to about 165–170 days; it has also provided FY27 revenue and profit guidance.
Key risks
Debtor days reached 203 in FY26, leaving substantial amounts waiting to be collected; margins may also be affected by product-mix changes.
Maxgrow’s low valuation and profits
Potential strengths
The company reported five consecutive quarters of rising profit, and its shares trade at a reported PE of about 1.2.
Key risks
The auditor raised concerns, several financial statement lines were reported as zero, and the article says the low public float and high promoter ownership create uncertainty.
- Kwality one-year share-price rise
- 296%, to about Rs 3,590 as of 8 October 2026
- Kwality June 2026 quarter
- Sales of Rs 162 crore and net profit of Rs 26 crore
- Kwality debtor days
- 203 in FY26; management said receivables improved to about 165–170 days by the June 2026 quarter
- Kwality FY27 guidance
- Revenue above Rs 700 crore and profit above Rs 109 crore
- Maxgrow one-year share-price rise
- 852%, to about Rs 181 as of 8 October 2026
- Maxgrow June 2026 quarter
- Sales of Rs 7,385 crore and net profit of Rs 199 crore
- Maxgrow auditor review
- The December 2025 quarterly review carried a qualified conclusion and flagged several recordkeeping, filing, audit, and governance concerns.
- Maxgrow share ownership
- The promoter held more than 90%, leaving less than 10% with public shareholders, according to the article.